Alleviating the storm: ruxolitinib in HLH
- PMID: 27034417
- DOI: 10.1182/blood-2016-02-697151
Alleviating the storm: ruxolitinib in HLH
Abstract
In this issue of Blood, Das and colleagues report their results on the use of the Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib in murine models of hemophagocytic lymphohistiocytosis (HLH), and the HLH-sibling macrophage activation syndrome (MAS).
Comment on
-
Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis.Blood. 2016 Mar 31;127(13):1666-75. doi: 10.1182/blood-2015-12-684399. Epub 2016 Jan 29. Blood. 2016. PMID: 26825707 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous

